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Highlights 
• Primary hepatocytes offer a simple in vitro model for pharmacokinetic studies. 
• The utility of hepatocytes for prediction of in vivo clearance of drugs or novel 
chemical entities may have some limitations. 
• In vitro pharmacokinetic behaviour of psychopharmacons in rat hepatocytes correlated 
with in vitro human pharmacokinetics. 
• Neither the elimination rates nor the intrinsic clearance in dog or rabbit cells 
resembled those parameters in human cells. 
• For prediction of in vivo hepatic clearance, rat hepatocyte model appeared to be the 
most relevant to human. 
• Human bioavailability values predicted from in vitro clearance were in good agreement 
with clinical bioavailability data. 
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Abstract 
Primary hepatocytes offer a simple in vitro model for studying biotransformation of drugs or 
novel chemical entities. The utility of hepatocytes for the prediction of in vivo clearance was 
investigated by using 16 psychopharmacons of disparate structures (aripiprazole, biperiden, 
carbamazepine, citalopram, clonazepam, clozapine, duloxetine, fluoxetine, haloperidol, 
mianserin, mirtazapine, olanzapine, paroxetine, quetiapine, risperidone, venlafaxine). In vitro 
pharmacokinetic parameters (t1/2 elimination half-life, Clint intrinsic clearance) were determined 
in human, rat, dog and rabbit hepatocytes by liquid chromatography tandem mass spectrometry, 
and hepatic clearance values (ClH), hepatic extraction ratios as well as bioavailability values 
were predicted. 
In human hepatocytes, the most stable compounds were carbamazepine, citalopram, 
clonazepam, fluoxetine, mirtazapine and paroxetine, displaying in vitro t1/2 longer than the 
5-hour incubation period, whereas quetiapine appeared to be the most labile drug. The fastest 
elimination rates were observed in rabbit hepatocytes, with approximately one or two 
magnitude orders faster than in human liver cells. In vitro pharmacokinetic parameters obtained 
from rat hepatocytes displayed strong correlation with in vitro human values (r2>0.85); whereas 
neither the elimination rates nor Clint of the drugs in dog or rabbit hepatocytes resembled 
those parameters in human cells (r2<0.2). Similarly, there were significant interspecies 
differences in hepatic clearance predicted from in vitro elimination half-lives. Namely 
significant correlation was observed in predicted ClH values between human and rat, and no 
correlation was found between human and dog or rabbit. The human hepatic extraction ratios 
of the psychopharmacons ranged widely from the lowest values for carbamazepine and 
clonazepam (<0.1) to the highest for quetiapine (0.7). The human bioavailability values 
predicted from in vitro pharmacokinetic data were in good agreement with clinical 
bioavailability data.  
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In conclusion, the predicted bioavailability obtained from human hepatocytes showed an 
excellent rank order with in vivo findings. Furthermore, rat was considered to be the most 
relevant animal model to human subjects. 
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1. Introduction 
The early knowledge of the pharmacokinetic behaviour and the routes by which a novel drug-
candidate is metabolized is important for the interpretation of toxicological data obtained in 
safety studies and for prediction of in vivo systemic clearance in human [1, 2]. The hepatic 
metabolic clearance is considered to be the major component of the total clearance [3]; thus, in 
the early phase of drug development, hepatic stability screening is a widely used method to 
assess the metabolic stability and to predict in vivo hepatic clearance of a drug candidate [1, 4]. 
For in vivo clearance prediction, theoretical aspects of in vitro – in vivo scaling have been 
developed and successfully established in laboratory animals or in human [5-9]. The first 
attempt by Rane et al [10] calculated in vivo clearance from intrinsic clearance of a drug which 
was obtained by determination of the enzyme kinetic constants (vmax: maximal velocity of 
enzyme activity, KM: Michaelis constant) in hepatic microsomal metabolism. The in vitro t1/2 
method described by Obach [6] is based on determination of the first-order rate constant for 
consumption of the drug-substrate for the estimation of intrinsic clearance.  
The potential advantages of in vitro pharmacokinetic approach include the rapid distribution of 
the test compound, rapid sampling for kinetic studies, relatively high purity of the biological 
samples and the easy procedure of the determination of depletion of the parent compounds. 
An appropriate in vitro model should resemble the in vivo metabolism; thus for successful 
prediction of in vivo clearance, the selection of in vitro models must consider the qualitative 
information on enzyme(s) responsible for the metabolism of a drug [1, 6, 7, 11-15]. Several in 
vitro models have been developed, such as supersomes (expressed enzymes), subcellular 
fractions (microsomes, cytosol or S9 fraction), primary hepatocytes (freshly isolated or 
cryopreserved) or intact perfused liver, and some of these models are acceptable as supportive 
test systems by the regulatory authorities. Hepatic microsomes are simple, affordable and can 
be a useful in vitro model for evaluating pharmacokinetics of drugs metabolized by cytochrome 
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P450 (CYP) enzymes [5, 6]; however, this model has some drawback in studying those 
compounds that are metabolized by non-microsomal enzymes or by microsomal 
UDP-glucuronyltransferases. Conjugation activities in microsomal preparations generally 
underpredict in vivo metabolism because of the lack of conjugation enzymes (non-microsomal 
localisation) or insufficient activation of UDP-glucuronyltransferase activities [16]. Several 
authors [5; 12] successfully applied primary hepatocytes for in vitro studies and demonstrated 
better predictability of in vivo clearance. The advantages of hepatocytes over subcellular 
fractions have been documented; namely the cells retain most of the metabolic capabilities of 
the intact liver, possess the full complement of drug-metabolizing enzymes and contain the 
cofactors at physiological concentrations [5, 7, 12, 13]. Additional advantages of hepatocytes 
are the possibility of determination of metabolic profiles or even of metabolite identification. 
Hepatocytes in suspension are appropriate for the investigation of pharmacons with short 
elimination half-lives (<5 hr), whereas liver cells attached on collagene surface are generally 
applied for drugs with long half-lives (>5 hr). In high-throughput studies, the 
multi-drug-in-one-cocktail approach can be an option; however, the metabolism-based 
drug-drug interactions must be excluded for appropriate evaluation. In vitro pharmacokinetic 
data obtained from human hepatocytes can be used for prediction of in vivo hepatic clearance in 
human, whereas in vitro clearance data from hepatocytes isolated from rat, mouse, dog or rabbit 
can be useful to identify the laboratory animal(s) with similar pharmacokinetics to human 
beings. Furthermore, information on species differences in the rates and pathways of 
metabolism is of great interest and can help to select the laboratory animal model most 
relevant to human and most suitable to study the toxic properties of drugs. 
In the present study, we investigated in vitro pharmacokinetics of sixteen psychopharmacons 
with disparate chemical structures (aripiprazole, biperiden, carbamazepine, citalopram, 
clonazepam, clozapine, duloxetine, fluoxetine, haloperidol, mianserin, mirtazapine, olanzapine, 
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paroxetine, quetiapine, risperidone, venlafaxine, Fig. 1) in primary hepatocytes of rat, rabbit, 
dog and human using liquid chromatography tandem mass spectrometric (LC-MS/MS) analysis. 
These antipsychotics, antidepressants, mood stabilizers and anticonvulsive agents are most 
frequently used in treatment of psychiatric disorders (e.g. schizophrenia, schizoaffective 
disorder, bipolar disorder, depressive disorder). In vivo pharmacokinetic parameters (hepatic 
clearance, hepatic extraction ratio, bioavailability) were calculated from in vitro clearance data 
using in vitro t1/2 method. In vivo bioavailability of the psychopharmacons predicted from 
human hepatocytes was compared to in vivo clinical data. 
 
2. Materials and methods 
2.1 Chemicals 
Biperiden, carbamazepine, citalopram, clozapine, fluoxetine, mianserin, mirtazapine, 
paroxetine, risperidone and venlafaxine were purchased from Sigma-Aldrich Co. 
(Deisenhofen, Germany). Aripiprazole and duloxetine were obtained from International 
Laboratory USA (San Francisco, CA). Olanzapine and quetiapine was from Santa Cruz 
Biotechnology Inc. (Heidelberg, Germany). Clonazepam was obtained from Roche 
Magyarország Ltd. (Budaörs, Hungary) and haloperidol was from Gedeon Richter Plc. 
(Budapest, Hungary). All the other chemicals for the hepatocyte isolation and for the 
LC-MS/MS analysis were purchased from Merck (Darmstadt, Germany) and Sigma-Aldrich 
Chemie. 
2.2 Hepatocyte isolation 
Experiments were carried out by using pooled hepatocytes prepared from male Wistar rats, 
male Beagle dogs or male New-Zealand rabbits (Toxi-Coop Toxicological Research Center, 
Budapest, Hungary). Human liver tissues were obtained from organ-transplant donors at the 
Department of Transplantation and Surgery, Semmelweis University (Budapest, Hungary). 
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The liver cells were isolated using collagenase perfusion method of Bayliss and Skett [17]. 
Briefly: The liver tissues were perfused through a derivation of the portal vein with Ca2+-free 
medium (Earle’s balanced salt solution) containing EGTA (0.5 mM) and then with the same 
medium without EGTA, finally with the perfusate containing collagenase (Type IV, 
0.25 mg/ml) and Ca2+ at physiological concentration (2 mM). The perfusion was carried out at 
pH 7.4 and at 37°C. Hepatocytes having a viability of better than 90%, as determined by 
trypan blue exclusion [18], were used in the experiments. 
2.3 In vitro pharmacokinetics in primary hepatocytes 
Time courses of the unchanged psychopharmacons in hepatocytes pooled from three subjects 
were obtained. Each compound was incubated in cell suspension (generally at the 
concentration of 2×106 cells/ml; and at the concentration of 0.5 ×106 cells/ml or 4×106 
cells/ml with the drugs intensively or slowly metabolized, respectively) at 37°C in a humid 
atmosphere containing 5% CO2. The parent compounds were added directly to the medium 
(Williams’ medium E : Ham’s nutrient mixture F12 =1:1) at the final concentration of 1 µM. 
Except for clonazepam and haloperidol that were dissolved in medium, the stock solutions of 
the psychopharmacons (1 mM) were prepared in acetonitrile; thus, the final concentration of 
the organic solvent was 0.1% of the incubation mixture. At various time points (0, 5, 10, 15, 
20, 30, 45, 60, 90, 120, 240, 300 min), the incubation mixtures were sampled (aliquots: 
0.25 ml) and terminated by the addition of 0.17 ml ice-cold acetonitrile containing the internal 
standard, carbamazepine (0.13 µM) or clozapine (0.09 µM). The cell debris was separated by 
centrifugation and the supernatant was analysed by LC-MS/MS for quantitation of the parent 
compound. All measurements were performed in duplicate with <5% interday and intraday 
precision. 
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2.4 Determination of unchanged drug concentrations 
An Inertsil ODS-4 column (75×2.1 mm, 3 µm, GL Sciences Inc., Tokyo, Japan) with gradient 
elution was applied with MilliQ water containing 0.1% of formic acid as the mobile phase A 
and with acetonitrile containing 0.1% of formic acid as the mobile phase B. The column was 
eluted at a rate of 0.3 ml/min at 25°C using an Agilent 1100 HPLC-system (Agilent 
Technologies Inc., Waldbronn, Germany). The running time of chromatographic separation 
was 10 min, and the effluent was analysed by mass spectrometry. MS/MS measurements were 
performed on a SCIEX API 2000 mass spectrometer (Applied Biosystems, Foster City, 
Canada) using the Analyst 1.4.2 software. The ionisation mode was electrospray in positive 
mode. The instrument was used in multiple reaction monitoring (MRM) mode for quantitation 
of the psychopharmacons. The source conditions were: curtain gas: 30 units, spray voltage: 
5500 V, source temperature: 400°C, nebulising gas: 50 units, drying gas: 50 units. The MRM 
transitions and collision energy applied for monitoring the parent compounds are in Table 1. 
The primary stock solutions of psychopharmacons for the preparation of calibrator and quality 
control samples were prepared in acetonitrile or in water by separate weighing. The working 
solutions used for spiking the calibrator and quality control samples were diluted separately in 
acetonitrile by spiking an appropriate volume of the stock solutions to achieve the 
concentrations ranged between 1 and 0.05 mM. The working solutions were 1000 times 
diluted in cell culture medium to achieve the final concentrations (1-0.05 µM), and after 
adding 0.17 ml acetonitrile containing the internal standard (0.13 µM carbamazepine or 0.09 
µM clozapine), the calibrators were analysed by LC-MS/MS. 
2.5 Estimation of pharmacokinetic parameters 
The intrinsic clearance for hepatocytes (Clint) [ml/(min×2x106cells)] was calculated from the 
decrease in the concentration of the psychopharmacon as follows [6]: 
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Clint=
2/1
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t
=β  
For scaling up the Clint value to obtain Clint per whole liver (g)/bw (kg), the cell concentration in liver, 
the average liver weight and average body weight parameters were used (Table 2) [19]. The 
value for hepatic clearance (ClH) was calculated as follows [1, 5, 8]:  
plasmabwliver
plasmabwliver
H QfuCl
QfuCl
Cl
+
=
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/int
/int  
where the flow rate of Qplasma=QH*plasma/blood ratio. To calculate ClH, the hepatic flow rate 
(Table 2), plasma/blood ratio=0.57 and fu=1 values were used [20]. (QH is the hepatic blood 
flow, while fu is the unbound fraction of the compound.) The hepatic extraction ratio was 
defined as [5, 12]: 
E=ClH*QH 
and the bioavailability (%) was [3] 
F=(1-E)*100. 
 
2.6 Data analysis 
The intrinsic clearance and predicted hepatic clearance of each psychopharmacon were 
calculated from in vitro pharmacokinetics in hepatocytes of human and laboratory animals. 
The correlation between the clearance values in human and in laboratory animals was 
estimated. The correlation among human and laboratory animal clearance was quantified, and 
the correlation coefficients (r2) were calculated using the Pearson approach (GraphPad InStat 
version 3.05, San Diego, CA). A strong correlation between the human and the animal 
clearance values was considered if the probability value (P) was under 0.05. 
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3. Results and Discussion 
3.1 In vitro pharmacokinetics of psychopharmacons in primary hepatocytes 
In vitro Clint was estimated for sixteen psychopharmacons with diverse chemical structures in 
primary hepatocytes of rat, rabbit, dog and human (Fig. 1). The time courses of unchanged 
parent compounds were determined, and the elimination half-life of each compound was 
calculated (an example of paroxetine in Fig. 2). The unchanged drug profiles at the 
concentration of 1 µM displayed linear log concentration declines; thus, the 
biotransformation follows a first-order reaction kinetics under these conditions. The 
metabolic stability of the set of psychopharmacons varied in a wide range, and large 
interspecies differences were observed in the pharmacokinetic behaviour of these drugs. In 
human hepatocytes, the most stable compounds were carbamazepine, citalopram, 
clonazepam, fluoxetine, mirtazapine and paroxetine, displaying in vitro elimination half-lives 
longer than the 5-hour incubation period. Similarly to human, slow elimination rates of these 
drugs were also observed in rat hepatocytes (Fig. 3a); however, the elimination half-lives 
were about one order of magnitude lower in the rat cells than in human hepatocytes. Besides 
carbamazepine and clonazepam, haloperidol was found to be the most stable drug in dog 
hepatocytes, whereas mirtazapine and paroxetine belonged to the most labile compounds in 
dog cells. In contrast to human, rat and dog, risperidone displayed the longest elimination 
half-life (in vitro t1/2 longer than the 5-hour incubation period) and the lowest Clint in rabbit 
liver cells. Quetiapine appeared to be the most labile compound in all species except for dog. 
Mianserin was found to be one of the most labile drugs in hepatocytes isolated from 
laboratory animals. Interestingly, mirtazapine and paroxetine, which were the most stable 
psychopharmacons in human and rat, appeared to be fast-elimination drugs in dog and rabbit 
liver cells. In general, the rabbit hepatocytes were found to have the most active metabolic 
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capability displaying elimination half-life shorter than 15 min for 12 of the set of 
psychopharmacons investigated. 
Species comparison of the in vitro pharmacokinetic behaviour of the set of 
psychopharmacons demonstrated that the metabolic capabilities of human and rat 
hepatocytes closely resembled each other, displaying strong correlation of in vitro t1/2 or Clint 
(r2=0.8878 and 0.9516, respectively) (Fig. 3). However, in human hepatocytes, the 
elimination half-lives were approximately 5 times longer, whereas the Clint values were about 
27 times lower than in rat cells. On the other hand, neither the elimination rates nor Clint of 
the drugs in human liver cells correlated with those parameters in dog or rabbit hepatocytes 
(r2<0.2). 
3.2 Prediction of human clearance and bioavailability of psychopharmacons from in vitro 
pharmacokinetic data 
The in vitro Clint values were expressed per kg of body weight taking physiological 
parameters, such as cell number in the liver, liver weight and body weight, into consideration 
(Table 2) (see 2.5). The calculation of hepatic clearance (ClH) additionally takes hepatic flow 
rate into account. In human, low hepatic clearance was predicted for aripiprazole, 
carbamazepine, citalopram, clonazepam, fluoxetine, mirtazapine and paroxetine, intermediate 
ClH was estimated for biperiden, clozapine, duloxetine, haloperidol, mianserin, olanzapine, 
risperidone and venlafaxine, whereas the hepatic clearance of quetiapine was predicted to be 
high (Fig. 4a). Similarly to the Clint (3.1), there were significant interspecies differences in 
hepatic clearance predicted from in vitro elimination half-lives. The predicted hepatic 
clearance for the psychopharmacons displayed significant correlation between human and 
rat, whereas neither dog nor the rabbit hepatic clearance resembled human ClH values (Fig. 
4). This means that in safety studies, the rat is the most relevant laboratory animal to human, 
since the metabolic properties of the rat is similar to those of human. During drug 
12 
 
development, the experimental approaches are generally based on animal models; however, 
the drug metabolizing systems in the laboratory animals can differ from each other or from 
human [21-24]. For example in rabbit, the enzymes of CYP2C subfamily are the most 
important in drug metabolism, contrary to human where CYP3A enzymes are involved in the 
metabolism of most of the drugs (approximately 50%) in the market [22, 25]. Additionally, 
CYP2D orthologues in rabbit have a marginal role in biotransformation, whereas CYP2D6 in 
human catalyses the metabolism of 30% of drugs despite the fact that the concentration of 
CYP2D6 protein is about 2% of the total hepatic CYP enzymes [25]. Because of the 
substantial metabolic differences between rabbit and man, the predictive value of the rabbit 
model can be considered to be poor [22]. The properties of the dog CYP2D15 mostly 
resembles the human CYP2D6; thus, dog model may be recommended for investigation of 
the drugs that are known to be metabolized by CYP2D6 in human [21, 22]. Although plenty 
of the psychopharmacons included in the present study are known to be metabolized by 
CYP2D6 (aripiprazole, citalopram, duloxetine, fluoxetine, haloperidol, mianserin, mirtazapine, 
olanzapine, paroxetine, quetiapine, risperidone, venlafaxine) [26], no correlation of the 
clearance properties was observed between the dog and the human hepatocytes. It can be 
explained by the facts 1) that some human CYP2D6 substrates are not metabolized or poorly 
metabolized by the canine CYP2D15 [24] or 2) that the dog CYP2D15 or the human 
CYP2D6 are not the exclusive enzymes in the metabolism of most of the drugs. 
Hepatic clearance predicted from in vitro pharmacokinetic parameters allows the 
classification of drugs into low, intermediate and high hepatic extraction ratio (E) groups. 
Houston [5] suggested the cut-off values between the hepatic extraction ratio groups: under 
0.3 for low extraction drugs, between 0.3 and 0.7 for intermediate, and above 0.7 for high 
extraction drugs. Considering these cut-off values, the psychopharmacons displaying low 
hepatic clearance in human hepatocytes were classified as low extraction drugs, those having 
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intermediate ClH were intermediate extraction compounds, whereas quetiapine with high 
hepatic clearance was a high extraction drug (Fig. 4 and Table 3). Significant interspecies 
differences in hepatic extraction properties of the psychopharmacons were observed 
(Table 3), anticipating different systemic exposure of the laboratory animals and human at 
the same dose level. In rabbit, three fourth of the psychopharmacons were classified as high 
extraction drugs, and only one, risperidone displayed low hepatic extraction (E=0.08). 
Risperidone was found to be an intermediate or high extraction compound in the species 
other than rabbit. In rat and dog, 56% of the drugs were high extraction compounds, and only 
carbamazepine was classified as a low extraction drug in dog (E=0.27). 
In vitro pharmacokinetic behaviour of a drug provides useful information for the prediction 
of bioavailability. The bioavailability of the psychopharmacons was predicted from in vitro 
pharmacokinetic parameters obtained in human hepatocytes, and the predicted values were 
compared with in vivo oral bioavailability determined in clinical studies (Table 4) [26-32]. 
The human bioavailability predicted from in vitro pharmacokinetic studies appeared to be in 
good agreement with in vivo clinical data, which confirmed the utility of the primary 
hepatocyte model for prediction of in vivo pharmacokinetic parameters. This also means that 
the precision of in vivo prediction from in vitro data was found to be excellent, and that the in 
vitro approaches can be recommended for assaying drug-candidates in a prospective manner. 
 
4. Conclusions 
The rate of metabolism of a drug influences both its pharmacodynamic effect and its toxic 
potential; thus, pharmacokinetic studies are essential for understanding the results of safety 
studies on a drug-candidate. In the early phase of drug development, there is an urgent need to 
predict the in vivo pharmacokinetic behaviour of a molecule in human. Therefore, substantial 
efforts have been made in development of metabolically competent in vitro models 
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appropriate for the extrapolation to in vivo with acceptable degree of confidence. Primary 
hepatocytes offer a simple in vitro model because the cells provide an opportunity to study in 
vitro biotransformation of novel chemical entities and to predict in vivo pharmacokinetic 
parameters. The present study with sixteen psychopharmacons (antipsychotics, 
antidepressants, mood stabilizers) demonstrated the utility of in vitro pharmacokinetic data 
obtained from primary liver cells isolated from human in prediction of in vivo hepatic 
clearance and bioavailability. The predicted human bioavailability showed an excellent rank 
order with in vivo clinical data. The comparison of in vitro Clint or predicted hepatic clearance 
values in human with those obtained from hepatocytes of laboratory animals indicated that the 
metabolism mediated species differences should be taken into account in in vitro-in vivo 
extrapolation. Rat hepatocytes were considered to be the most relevant in vitro animal model 
to human, whereas the knowledge of the pharmacokinetic differences between human and dog 
or rabbit facilitates the interpretation of the results of safety studies in these animal models. 
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Table 1 The MRM transitions and collision energy applied for monitoring of 
psychopharmacons 
 
Psychopharmacon Q1 (amu) Q3 (amu) Collision energy (eV) 
Aripiprazole 449.2 286.1 39 
Biperiden 312.2 98.1 35 
Carbamazepine 237.1 194.1 30 
Citalopram 325.0 108.9 37 
Clonazepam 316.0 269.9 37 
Clozapine 327.1 270.1 33 
Duloxetine 298.1 154.0 9 
Fluoxetine 309.9 44.0 32 
Haloperidol 376.1 164.9 34 
Mianserin 265.2 208.0 30 
Mirtazapine 266.2 195.0 35 
Olanzapine 313.3 256.1 31 
Paroxetine 330.2 192.1 30 
Quetiapine 384.1 253.0 32 
Risperidone 411.1 191.1 40 
Venlafaxine 278.2 58.0 40 
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Table 2 Physiological parameters for calculation of clearance values 
 
Parameter* Rat Rabbit Dog Human 
Number of hepatocytes in liver 
(×106 cells /g liver) 117 114 215 139 
Liver weight (g) 10 77 320 1.660 
Body weight (kg) 0.25 2.5 10 70 
Liver blood flow (ml/min/kg) 55.2 70.8 30.9 19 
*[19, 20] 
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Table 3 Extraction ratio values of psychopharmacons predicted in hepatocytes from human, 
rat, dog and rabbit 
 
Psychopharmacon Extraction ratio 
 Human Rat Dog Rabbit 
Aripiprazole 0.24 0.51 0.94 0.32 
Biperiden 0.34 0.90 0.66 0.96 
Carbamazepine <0.14 0.46 0.27 0.34 
Citalopram 0.19 0.49 0.53 0.79 
Clonazepam <0.14 0.44 0.36 0.33 
Clozapine 0.38 0.85 0.91 0.73 
Duloxetine 0.45 0.83 0.98 0.92 
Fluoxetine 0.16 0.43 0.45 0.85 
Haloperidol 0.30 0.77 0.35 0.77 
Mianserin 0.36 0.84 0.99 0.93 
Mirtazapine 0.18 0.38 0.94 0.89 
Olanzapine 0.43 0.91 0.75 0.87 
Paroxetine 0.19 0.42 0.98 0.75 
Quetiapine 0.70 0.96 0.85 0.92 
Risperidone 0.37 0.80 0.71 0.08 
Venlafaxine 0.31 0.75 0.56 0.84 
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Table 4 Comparison of bioavailability of psychopharmacons predicted in human hepatocytes 
with in vivo bioavailability data 
 
Psychopharmacon Bioavailability (%) 
 Predicted in human hepatocytes 
In vivo bioavailability 
(clinical data)* 
Aripiprazole 76.3 70-90 
Biperiden 65.7 40-87 
Carbamazepine >86.1 89-100 
Citalopram 81.5 80 
Clonazepam >86.1 80-98 
Clozapine 61.6 50-60 
Duloxetine 54.8 50 
Fluoxetine 84.1 70-85 
Haloperidol 69.6 60-70 
Mianserin 64.4 30-80 
Mirtazapine 81.5 50-75 
Olanzapine 56.9 60-80 
Paroxetine 80.9 60-100 
Quetiapine 30.7 30 
Risperidone 63.1 70 
Venlafaxine 69.4 45-92 
* [26-32] 
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Figure legends 
Figure 1. Chemical structures of the model psychopharmacons. 
Figure 2. The time course of paroxetine depletion in primary hepatocytes.  
The hepatocyte concentrations were 2×106/ml for rat and human; and 0.5×106/ml for 
dog and rabbit. The starting concentration of paroxetine was 1 µM. 
Figure 3. Correlation of the elimination half-life and Clint values of the psychopharmacons 
between human and rat hepatocytes.  
Ari: aripirazole, Bip: biperiden, Carb: carbamazepine, Cit: citalopram, Clon: 
clonazepam, Clz: clozapine, Dulo: duloxetine, Fluo: fluoxetine, Hal: haloperidol, Mia: 
mianserin, Mirt: mirtazapine, Ola: olanzapine, Par: paroxetine, Quet: quetiapine, Risp: 
risperidone, Ven: venlafaxine 
Figure 4. Correlation of the hepatic clearance values predicted from in vitro pharmacokinetic 
parameters. 
(a) correlation between human and rat, (b) between human and dog, (c) between 
human and rabbit 




